Revista de gastroenterologia de Mexico (English)
Cure8 research brief
Why This Matters
People with IBD and their clinicians need to know whether common IBD treatments change COVID-19 risk or should be stopped. This review provides practical recommendations (continue most maintenance drugs; avoid systemic steroids when possible; pause biologics if infected) based on early pandemic evidence.
Who Should Pay Attention
Adult patients with IBD, clinicians treating IBD, and patients on immunomodulators or biologics
Study Snapshot
Story typeClinical Reference
Evidence typeResearch paper
Source depthFull source text
What To Know
The article reports that available evidence at the time did not show higher risk of SARS-CoV-2 infection for people with IBD.
It states that 5-ASA medications (mesalamine/sulfasalazine) and immunomodulators (thiopurines, methotrexate) generally should be continued, and that systemic corticosteroids above ~20 mg/day carry immunosuppressive risk and should be avoided when possible.
The review recommends optimizing topical/oral 5-ASA for relapse and considering budesonide MMX for mild–moderate activity to limit systemic steroid use. It advises suspending biologic therapy (including anti-TNF, anti-integrin, anti-interleukin agents) if a patient becomes infected with SARS-CoV-2, restarting after the infection resolves.
Keep In Mind
The paper is a review from early in the COVID-19 pandemic that synthesizes observational reports and society guidance available at that time; recommendations may have changed as more data accumulated.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationRevista de gastroenterologia de Mexico (English)
Study typeResearch Article, journal article
Indexed viaEurope PMC
Source typeResearch paper
PublishedJan 1, 2020, 12:00 AM
Content availableFull source text
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
A Case of Elderly-Onset Ulcerative Colitis with Large-Vessel Giant Cell Arteritis Treated Successfully with Tofocitinib.
Older adults with ulcerative colitis can rarely develop large-vessel giant cell arteritis as an extraintestinal complication.
Do You Need to Treat Asymptomatic Crohn’s Disease?
You can have active intestinal inflammation even without clear symptoms; early monitoring and tailored treatment aim to prevent complications and preserve quality of life.
Escalating Crohn's Care: The Case for Dual Therapy - Medscape
Combination (dual) therapy is an active area of research because many people with Crohn’s disease don’t achieve lasting remission on a single advanced therapy. New trials suggest some combinations may improve remission...